Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection

Shanghai Jiao Tong University School of Medicine

Status and phase

Unknown

Phase 2

Conditions

Leukemia

Transplantation, Hematopoietic Stem Cell

Treatments

Drug: Caspofugin based combination therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT01501708

RJH-2011-71

Details and patient eligibility

About

In this prospective phase II observational study, we plan to assess the efficacy and tolerability of caspofungin based combined anti-fungal therapy for proven or probable IFI in a group of patients received allo-HSCT transplantation with high risk of IFI: HLA matched unrelated donor or mismatched donor conditioning with ATG containing regimen or present III-IV aGVHD or extensive GVHD undergoing high-dose steroid treatment.

Full description

Patients will recieve caspofungin with either voriconazole or amphotericin B as combination therapy for fungal infection

Enrollment

55 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

adult patient undergoing allogeneic hematopoietic stem cell transplantation
age 18-55 years
with inform consent
no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage
HLA mismatched related (3~5/6) or unrelated donors (at least 8/10)
proven or probable IFI

Exclusion criteria